Background and Aims Management of ultrasound (US)-guided percutaneous liver biopsy (PLB) lacks standardisation. Despite the low risk of major complications (< 1%), repeated blood counts and up to 4 h of in-hospital observation are typically recommended. We aimed to assess complication rates and predictors in a large cohort of patients undergoing US-PLB across three Italian tertiary centres. We included all patients undergoing US-PLB from January 2018 to December 2023. We collected clinical, biochemical and procedural features (needle type, insertions number, observation time and antiplatelet/anticoagulant regimens). Safety was assessed by the incidence of pain and major complications, including vasovagal reaction, bleeding, pneumothorax, shock, hospitalisation and death. Approach and Results Among 1838 patients (mean age 55.1 years, 46.1% females, mean BMI 25.1 kg/m(2), 74% parenchymal PLB), few were on anticoagulant/antiplatelet therapy (4.2%/16.2%); mean platelet count and PT INR were 209.7 x 10(3)/mm(3 )and 1.04; 17 patients (0.9%) received prophylactic therapy (blood components, thrombopoietin receptor agonists or vitamin K). Needle aspiration was predominant (92%). During a mean time of observation of 5.4 +/- 2.0 h, 134/1838 patients reported pain (7.4%). Major complications were few (26, 1.4%), with 14 episodes of transient hypotension (0.8%); 10 bleeding events (0.5%); 1 pneumothorax; 1 abscess formation; 1 haemobilia; and 1 episode of chest pain. Hospitalisation was rare (12, 0.7%), primarily for bleeding management. No fatalities were recorded. Pain was the sole significant independent predictor of major complications (18/26, HR 30.6, p < 0.05), particularly when reported within the first hour post-procedure (15/18, 83.3%). Conclusions Major complications following US-PLB are few and strongly associated with early post-procedural pain. In the absence of pain within the first hour, extended monitoring may be unnecessary, allowing for earlier patient discharge.

Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study / F. Colapietro, M. Viganò, F. Cerini, R. Plebani, A. Savino, M. Calabrese, P. Marra, K. Martins de Mattos, S. Taboni, A. Cosenza, A. Loglio, C. Selvaggio, M. Lucà, C. Masellis, B. Mori, N. Pugliese, C. Masetti, E. Farina, S. De Nicola, R. Ceriani, A. Lleo, R. Muglia, S. Sironi, S. Fagiuoli, A. Aghemo. - In: LIVER INTERNATIONAL. - ISSN 1478-3231. - 45:5(2025 May), pp. e70078.1-e70078.8. [Epub ahead of print] [10.1111/liv.70078]

Incidence and Predictors of Complications Following Percutaneous Liver Biopsy: A Large Italian Multicentre Study.

F. Cerini;A. Cosenza;A. Loglio;C. Selvaggio;C. Masellis;
2025

Abstract

Background and Aims Management of ultrasound (US)-guided percutaneous liver biopsy (PLB) lacks standardisation. Despite the low risk of major complications (< 1%), repeated blood counts and up to 4 h of in-hospital observation are typically recommended. We aimed to assess complication rates and predictors in a large cohort of patients undergoing US-PLB across three Italian tertiary centres. We included all patients undergoing US-PLB from January 2018 to December 2023. We collected clinical, biochemical and procedural features (needle type, insertions number, observation time and antiplatelet/anticoagulant regimens). Safety was assessed by the incidence of pain and major complications, including vasovagal reaction, bleeding, pneumothorax, shock, hospitalisation and death. Approach and Results Among 1838 patients (mean age 55.1 years, 46.1% females, mean BMI 25.1 kg/m(2), 74% parenchymal PLB), few were on anticoagulant/antiplatelet therapy (4.2%/16.2%); mean platelet count and PT INR were 209.7 x 10(3)/mm(3 )and 1.04; 17 patients (0.9%) received prophylactic therapy (blood components, thrombopoietin receptor agonists or vitamin K). Needle aspiration was predominant (92%). During a mean time of observation of 5.4 +/- 2.0 h, 134/1838 patients reported pain (7.4%). Major complications were few (26, 1.4%), with 14 episodes of transient hypotension (0.8%); 10 bleeding events (0.5%); 1 pneumothorax; 1 abscess formation; 1 haemobilia; and 1 episode of chest pain. Hospitalisation was rare (12, 0.7%), primarily for bleeding management. No fatalities were recorded. Pain was the sole significant independent predictor of major complications (18/26, HR 30.6, p < 0.05), particularly when reported within the first hour post-procedure (15/18, 83.3%). Conclusions Major complications following US-PLB are few and strongly associated with early post-procedural pain. In the absence of pain within the first hour, extended monitoring may be unnecessary, allowing for earlier patient discharge.
complications; liver biopsy; liver diseases;
Settore MEDS-10/A - Gastroenterologia
mag-2025
1-apr-2025
Article (author)
File in questo prodotto:
File Dimensione Formato  
LIV-45- Incidence and Predictors of Complications Following Percutaneous Liver Biopsy.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 318.04 kB
Formato Adobe PDF
318.04 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1159096
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
  • OpenAlex ND
social impact